Publication Name	World Journal of Gastroenterology
Manuscript ID	63120
Country	Canada

Received	2021-01-25 00:19
Peer-Review Started	2021-01-25 00:23
First Decision by Editorial Office Director	2021-02-27 23:05
Return for Revision	2021-02-27 23:05
Revised	2021-03-04 19:25
Publication Fee Transferred
Second Decision by Editor	2021-04-12 12:51
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2021-04-13 14:15
Articles in Press	2021-04-13 14:15
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-04-22 06:58
Publish the Manuscript Online	2021-04-29 02:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	<Iitalic>BRCA</Italic> mutated pancreatic cancer: A change is coming
Manuscript Source	Invited Manuscript
All Author List	Michael N Rosen, Rachel A Goodwin and Michael M Vickers
ORCID	Author(s) ORCID Number Michael N Rosen http://orcid.org/0000-0002-6625-2230 Rachel A Goodwin http://orcid.org/0000-0002-0250-8479 Michael M Vickers http://orcid.org/0000-0002-2587-2265
Funding Agency and Grant Number
Corresponding Author	Michael M Vickers, FRCPC, MD, Assistant Professor, Doctor, Doctor, The Ottawa Hospital Cancer Center, The University of Ottawa, 501 Smyth Road, Ottawa K1H 8L6, Ontario, Canada. mvickers@toh.ca
Key Words	Pancreatic cancer; Systemic therapy; Platinum chemotherapy; Breast cancer susceptibility gene; Deoxyribonucleic acid repair; Poly (ADP-ribose) polymerase inhibitors
Core Tip	Recent advances in the field of breast cancer susceptibility gene (BRCA)-mutated pancreatic cancer suggest that these patients benefit from platinum-based chemotherapy regimens. In light of new findings from the Pancreas Cancer Olaparib Ongoing trial, patients with germline BRCA mutations may benefit from maintenance treatment with olaparib, a Poly (ADP-ribose) polymerase inhibitors following response to platinum-based chemotherapy. Based on these important findings, all pancreatic cancer patients should be offered early access to genetic screening in order to identify patients who will benefit from these therapies.
Publish Date	2021-04-29 02:12
Citation	Rosen MN, Goodwin RA, Vickers MM. Breast cancer susceptibility gene mutated pancreatic cancer: A change is coming. World J Gastroenterol 2021; 27(17): 1943-1958
URL	https://www.wjgnet.com/1007-9327/full/v27/i17/1943.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i17.1943

Full Article (PDF)	WJG-27-1943.pdf
Full Article (Word)	WJG-27-1943.docx
Manuscript File	63120_Auto_Edited_LM.docx
Answering Reviewers	63120-Answering reviewers.pdf
Audio Core Tip	63120-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	63120-Conflict-of-interest statement.pdf
Copyright License Agreement	63120-Copyright license agreement.pdf
Peer-review Report	63120-Peer-review(s).pdf
Scientific Misconduct Check	63120-Scientific misconduct check.pdf
Scientific Editor Work List	63120-Scientific editor work list.pdf
CrossCheck Report	63120-CrossCheck report.pdf